LOTUS PHARMACEUTICAL Business Summary

Lotus Pharmaceutical (1795.TW) operates a high-growth, vertically integrated pharmaceutical model, generating revenue through the development, manufacturing, and global commercialization of high-barrier generic and specialty drugs. The company’s primary business segments include a dominant oncology portfolio—anchored by the global export of Lenalidomide—as well as central nervous system (CNS), cardiovascular, and women’s health treatments. Following the strategic consolidation of Alvogen US in late 2025 and the integration of Teva’s Thai operations, Lotus has transitioned into a multinational platform with a dual-engine growth strategy: high-margin exports to the US and EU markets, and a robust direct-to-market commercial presence across Southeast Asia and Korea. In the competitive landscape, Lotus positions itself as a specialized, high-efficiency alternative to global generic giants like Teva Pharmaceutical Industries, Sandoz Group AG, and Viatris Inc., maintaining a competitive edge through its "Glocal" strategy that combines global R&D standards with localized Asian market access. Originally founded in 1966 by the Lin family, Lotus Pharmaceutical underwent a transformative restructuring in 2014 following a strategic investment by the Alvogen Group, led by current Chairman Robert Wessman. Wessman, a prominent industry veteran and founder of the investment firm Aztiq, brings a pedigree of aggressive global expansion from his tenure as CEO of Actavis. The executive leadership is headed by CEO Petar Vazharov, who has directed the company’s international pivot since 2017, drawing on over two decades of experience from senior roles at Actavis and Teva. The management team is further supported by Group CFO Bjartur Shen, who manages corporate strategy and financial operations, and COO Vamsi Kiran Kosaraju. Notable institutional backing includes Aztiq and Innopharma, with a board of directors that reflects a sophisticated international ownership structure focused on transitioning Lotus from a regional manufacturer into a top-tier global specialty pharmaceutical platform.